- Home
- MHUA vs AYTU Comparison
MHUA vs AYTU Comparison
Compare MHUA & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- AYTU
- Stock Information
- Founded
- MHUA 1990
- AYTU N/A
- Country
- MHUA China
- AYTU United States
- Employees
- MHUA N/A
- AYTU N/A
- Industry
- MHUA Medical Specialities
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- AYTU Health Care
- Exchange
- MHUA Nasdaq
- AYTU Nasdaq
- Market Cap
- MHUA 13.1M
- AYTU 8.3M
- IPO Year
- MHUA 2022
- AYTU N/A
- Fundamental
- Price
- MHUA $0.53
- AYTU $1.78
- Analyst Decision
- MHUA
- AYTU
- Analyst Count
- MHUA 0
- AYTU 0
- Target Price
- MHUA N/A
- AYTU N/A
- AVG Volume (30 Days)
- MHUA 301.1K
- AYTU 3.7M
- Earning Date
- MHUA 04-25-2025
- AYTU 05-14-2025
- Dividend Yield
- MHUA N/A
- AYTU N/A
- EPS Growth
- MHUA N/A
- AYTU N/A
- EPS
- MHUA 0.40
- AYTU N/A
- Revenue
- MHUA $96,909,642.00
- AYTU $77,691,000.00
- Revenue This Year
- MHUA N/A
- AYTU N/A
- Revenue Next Year
- MHUA N/A
- AYTU $8.14
- P/E Ratio
- MHUA $1.15
- AYTU N/A
- Revenue Growth
- MHUA N/A
- AYTU N/A
- 52 Week Low
- MHUA $0.25
- AYTU $0.95
- 52 Week High
- MHUA $1.47
- AYTU $3.23
- Technical
- Relative Strength Index (RSI)
- MHUA 74.87
- AYTU 55.38
- Support Level
- MHUA $0.38
- AYTU $1.90
- Resistance Level
- MHUA $0.50
- AYTU $2.70
- Average True Range (ATR)
- MHUA 0.05
- AYTU 0.19
- MACD
- MHUA 0.01
- AYTU -0.02
- Stochastic Oscillator
- MHUA 95.92
- AYTU 36.11
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.